What's New

  • Press Release: FDA Approves New Bladder Cancer Treatment

    The Bladder Cancer Advocacy Network (BCAN) applauds the U.S. Food and Drug Administration (FDA) approval of an innovative, first-of-its-kind bladder cancer treatment, establishing a brand new class of therapy for the disease. Genentech, a member of the Roche Group, produced this new treatment, TECENTRIQ™ (atezolizumab), which allows the body’s immune system to work more effectively to fight cancer.

  • Meet BCAN Volunteer Nancy Lindsey

    I was diagnosed with bladder cancer in 2006. I had blood in my urine – the specialists thought of everything else possibly causing this — but I believed there was more to it. I got a second opinion, and then nine months later came a confirmation of bladder cancer.

  • New Practice Guidelines for Non-Muscle Invasive Bladder Cancer Patients

    Two prominent medical organizations, the American Urological Association (AUA) and the Society for Urologic Oncology, recently released new practice guidelines for physicians caring for patients with non-muscle invasive bladder cancer.

  • Bladder cancer is the fifth most commonly diagnosed cancer in the U.S.
  • Nearly 77,000 new cases of bladder cancer are expected to be diagnosed in 2016.
  • More than 16,000 people will die from the disease this year alone.
  • Bladder cancer is three times more common in men than in women.
  • One in 42 people will be diagnosed with bladder cancer during their lifetime.
Click here for more details